218: Low dose ambisome anti-fungal prophylaxis in pediatric allogeneic unrelated hematopoietic stem cell transplant  by Shinkle, M. et al.
arms. The most frequently observed AEs were diarrhea, nausea,
vomiting, fatigue, and rash. The incidence of rash (40%, 36%,
46%, and 33% for Arms A, B, C, and D respectively) was compa-
rable with the previously reported palifermin AE proﬁle. Overall
summary of AEs is presented in Table 1. Conclusion: The toler-
ability of the palifermin collapsed pre-dose arms is similar to Arm
A, with an incidence of AEs across all arms that is consistent with
the expected palifermin safety proﬁle. These results suggest that a
single pre-dose schedule can be tolerated and is a more convenient
dosing schedule. Timing of palifermin in a collapsed dose admin-
istration regimen may affect the efﬁcacy of OM reduction. This
concept warrants further study.
Overall Summary of Adverse Events
Arm A
(N10)
Arm B
(N11)
Arm C
(N13)
Arm D
(N12)
Pts who had any AEs 9(90%) 10(91%) 12(92%) 12(100%)
Pts who had study drug-
related AEs 5(50%) 5(45%) 6(46%) 5 (42%)
Pts who had serious AEs 1(10%) 3(27%) 4(31%) 1 (8%)
Pts who had serious
study drug-related
AEs 0 (0%) 1 (9%) 0 (0%) 0 (0%)
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Invasive fungal infections (IFI) are a major cause of morbidity
and mortality following allogeneic hematopoietic stem cell trans-
plant (HSCT). To reduce the rate of IFI, in 1996 we initiated a
program of bi-weekly lipid-based Amphotericin prophylaxis for
patients receiving unrelated HSCT. A total of 76 consecutive
patients received transplants from unrelated donors (Cord, MUD)
between 1/1/1996 and 6/30/2005. Three patients with docu-
mented or suspected pre-HSCT IFI were excluded from analysis
due to ongoing anti-fungal therapy at HSCT. Four patients re-
ceived alternative prophylactic regimens by physician choice. An
additional 3 patients were excluded due to death prior to initiation
of anti-fungal prophylaxis. Thus, a total of 66 patients were
deemed evaluable in this retrospective analysis. Sixty-four received
Ambisome, 3mg/kg/dose twice weekly from day -1 thru day 100
post-HSCT. Two patients received bi-weekly Abelcet prophylaxis
due to Ambisome allergy. Treatment was reduced or held for
elevations of serum creatinine. Additional anti-fungal measures
included HEPA air ﬁltration, intranasal Amphotericin B, oral Clo-
trimazole and Nystatin. Median patient age at HSCT was 7.5 years
(range, 0-24). Indications for HSCT included ALL (33), AML
(13), CML (3), JMML (3), NHL (1), Aplastic Anemia (2), SCID
(2), Metabolic Disorder (5), Other (4). The majority of patients had
unrelated cord blood allografts (59) and received GVH prophylaxis
which included ATG, cyclosporine and steroids. IFI documented
by culture and/or histology during the prophylaxis period occurred
in 9 of 66 evaluable patients (14%). Causative organisms were
Aspergillus fumigatis (3), Aspergillus terreus (1), Candida parap-
sillosis (3), Candida tropicalis (1), Candida glabrata (1), Trichos-
poron (1). Sites of infection included blood (6), lung (4), other (2).
Death due to IFI occurred in 3 of 66 patients (4%). Grade III renal
toxicity occurred in 5 of 66 patients (8%); no grade IV renal
toxicity was seen. We conclude that Ambisome anti-fungal pro-
phylaxis is well tolerated and may reduce morbidity and mortality
due to IFI in high risk HSCT patients.
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Hepatic complications following allogeneic stem cell transplan-
tation(HSCT) are a source of morbidity and mortality. A correla-
tion exists between bilirubin levels(as a marker) and mortality and
evidence exists that bilirubin itself may be responsible for end-
organ damage. A study of 1400 HSCT patients found that an
increase in bilirubin from 1mg to 3mg regardless of cause(GVHD,
SOS, sepsis,etc.), was associated with a mortality hazards ra-
tio6.4. Mortality for bilirubin  4mg was 50%.(Gooley et al.
Hepatology 2005(41)345). Since correction of highly elevated bil-
irubin levels is seldom successful, early interventions are needed to
prevent toxicity. N-acetylcysteine(NAC) is an anti-oxidant, useful
at reducing stress from reactive oxygen species(ROS). Recipients of
allogeneic HSCT at NMH were initiated on iv NAC 100mg/kg/d
(4 daily doses). Criteria for use included 1) an increase in absolute
bilirubin 2.0 or 2) doubling of baseline bilirubin  1.6. All
patients received ursodiol 300mg po tid. 31 patients who received
NAC therapy for 7days and had complete laboratory data available
were evaluated to determine the efﬁcacy of NAC in preventing
complications of liver disease following allogeneic HSCT. Condi-
tioning regimens included.Busulfan /Fludarabine(n15) Busulfan/
Cytoxan(n3), Cytoxan /- Melphalan( n9), TBI/VP-16( n4).
Median day for initiation of NAC was 9 days post HSCT(range
-4-43). Median bilirubin level prior to NAC therapy was
2.8mg(range1.6-13.7). Response: 24/31(77%)had positive respons-
es(decreased from baseline), while in 7/31(23%) bilirubin increased
during the 7days of treatment.(p.001). Only 2/24 responders had
GVHD, while 5/7 non-respoders had GVHD. (p.0023:Fischers
Exact test). Baseline bilirubin differed between responders and
nonresponders(3.1 and 7.0 respectively:p.0023). Responders im-
proved liver toxicity grade(NCI criteria ) from grade 3 to grade
2(median bilirubin improved from 2.8mg/dl to 1.7mg/dl). 4 re-
sponders whose bilirubin increased after NAC was discontinued,
successfully responded after re-challenge. Overall 100day non-
relapse mortality22%: (Bu/Flu3/15(20%):Bu/CY0/3(0%):
TBI/VP3/4(75%):CY/Mel1/9(11%).
NAC was effective in preventing the upward trend of bilirubin
s/p HSCT, a complication associated with excess mortality. Initi-
ating therapy before bilirubin levels become excessively elevated
may improve successful outcomes. This preliminary data should
encourage future research in prevention of liver toxicity post
HSCT.
NAC therapy results
Conditioning regime n % responders (P)
Busulfan/Cytoxan 3 100
Busulfan/Fludarabine 15 80
TBI/VP-16 4 25
Cytoxan /- Melphalan
(non-myeloablative) 9 91
GVHD 7 28(.0023)
Bilirubin <3.1mg 24 72(.0023)
Bilirubin >7.0mg 7 28(.0023)
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